Swedish Orphan Biovitrum AB (publ) SOBI
Email when the signal or risk changes · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
The news check keeps the assessment current.
General analysis — not personal advice.
Existing position may be maintained at current valuation.
Strong Haematology growth, raised guidance and pipeline progress outweigh leverage and regulatory risks, supporting the HOLD signal.
The market reacts positively to the strong Q3 report, raised guidance and regulatory progress for Tryngolza despite some uncertainty around CEO transition.
HOLD is the call. Positive is the market mood. Low risk means less can go wrong.
Latest change
- 28 Oct 2026 — Report shows strong Haematology growth and raised guidance, driving positive market sentiment despite CEO change.
The full analysis is open. Follow the company free for the full change history — and email next time the picture changes.
Show all changes (8) — follow the company freeAbout the company
Swedish Orphan Biovitrum develops and commercializes medicines in hematology and immunology. The company shows strong growth driven by products such as Altuvoct, Doptelet and Gamifant. Operations are profitable with positive cash flow generation.
Bull case
Strong Q3 growth, raised full-year guidance and positive CHMP opinion for Tryngolza provide momentum around pipeline progress.
Bear case
High net debt after acquisitions and regulatory delays for NASP create uncertainty.
Sensitivity analysis
| Factor | If it weakens | If it strengthens |
|---|---|---|
| Altuvoct sales | Lower than expected growth → 2026 revenue forecast at risk of being missed. | Stronger sales → higher EBITA margin and raised guidance. |
| NASP approval | Further delays → postponed revenues from gout treatment. | Rapid approval → new revenue stream from 2027. |
Why this signal
Strong Haematology growth, raised guidance and pipeline progress outweigh leverage and regulatory risks, supporting the HOLD signal.
Recent news
Sobi published the Q3 report on 27 October with revenue of SEK 9,124 million and raised full-year guidance. SB1 Markets and Berenberg raised price targets to SEK 525 and SEK 600 respectively. Börje Ekholm is proposed as new chairman. Tryngolza EU decision expected in Q4 2026.